Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Anixa Biosciences, Inc. (ANIX)

4.08   -0.4 (-8.93%) 03-17 16:00
Open: 4.48 Pre. Close: 4.48
High: 4.64 Low: 4.08
Volume: 155,831 Market Cap: 126(M)

Technical analysis

as of: 2023-03-20 8:44:04 AM
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 5.37     One year: 5.96
Support: Support1: 3.77    Support2: 3.14
Resistance: Resistance1: 4.6    Resistance2: 5.11
Pivot: 4.53
Moving Average: MA(5): 4.25     MA(20): 4.4
MA(100): 4.58     MA(250): 4.04
MACD: MACD(12,26): -0.1     Signal(9): 0
Stochastic oscillator: %K(14,3): 32.9     %D(3): 36
RSI: RSI(14): 44
52-week: High: 6.25  Low: 2.5
Average Vol(K): 3-Month: 53 (K)  10-Days: 82 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ANIX ] has closed above bottom band by 14.3%. Bollinger Bands are 25.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 4.65 - 4.67 4.67 - 4.69
Low: 4.03 - 4.05 4.05 - 4.07
Close: 4.05 - 4.08 4.08 - 4.11

Company Description

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Headline News

Mon, 13 Mar 2023
Anixa Biosciences Announces No Accounts at Silicon Valley Bank ... - India

Mon, 13 Mar 2023
Anixa Biosciences Reassures Shareholders It Has No Accounts at ... - PR Newswire

Thu, 02 Mar 2023
Anixa Biosciences to Provide Corporate Update at its 2023 Annual ... - PR Newswire

Thu, 02 Mar 2023
Anixa Biosciences, Inc.'s (NASDAQ:ANIX) Profit Outlook - Simply Wall St

Tue, 21 Feb 2023
Anixa Biosciences Announces Formation of Breast Cancer Clinical ... - Yahoo Finance

Thu, 08 Dec 2022
Anixa Biosciences Announces Maximum Tolerated Dose Reached ... - PR Newswire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 31 (M)
Shares Float 0 (M)
% Held by Insiders 4.5 (%)
% Held by Institutions 11.8 (%)
Shares Short 574 (K)
Shares Short P.Month 587 (K)

Stock Financials

EPS -0.42
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.93
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) 0
Return on Equity (ttm) 0
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)

Stock Valuations

PE Ratio -9.72
PEG Ratio 0
Price to Book value 4.34
Price to Sales 0
Price to Cash Flow 0

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.